CBD is everywhere, but the rules are still inconsistent across states. A proposed federal framework could reduce “gotcha” compliance risk, stabilize supply chains, and open more mainstream retail lanes.

Congress is weighing a bipartisan bill that would allow regulated 21 plus sales of consumable hemp products like gummies, drinks, and inhalables. Here is what it could change for compliance, enforcement, and competition with licensed cannabis.

A bipartisan House proposal would bring federal FDA rules to CBD and certain hemp derived products, replacing today’s patchwork. Here is what it means for labeling, testing, distribution, and competition with licensed cannabis.

Regulatory tightening around hemp THC could reshape competition with regulated cannabis. As rules change, demand, distribution, and compliance costs will shift across the market.

Texas has massive cannabis upside, but policy around hemp derived THC will decide who captures market share. Competition and enforcement will shape how demand shifts as the medical program expands.

Competing Republican proposals aim to regulate hemp THC through limits, labeling, age restrictions, and testing. The outcome could reshape competition between hemp and regulated cannabis markets.

Florida lawmakers are considering an adult use cannabis proposal that would break up vertically integrated licenses and expand market participation. The move could reshape competition, licensing strategy, and business models in one of the country’s largest potential markets.

New Hampshire lawmakers have advanced legislation to legalize adult use cannabis and allow medical dispensaries to convert to for profit status. The move signals a structured new market with important implications for licensing and business models.

Legal and regulatory experts outline the policy arenas most likely to shape cannabis operations in 2026. For operators, this briefing highlights where compliance, enforcement, and market strategy will matter most.

New York’s cannabis market faces ongoing regulatory friction tied to illicit supply, uneven enforcement, and seed-to-sale tracking pressure. These challenges directly affect market stability and operator confidence.

Federal cannabis reform could ease long standing advertising restrictions, unlocking real growth opportunities across legal markets. Changes in federal posture may reshape how brands reach customers, build loyalty, and scale responsibly.

A senior Pennsylvania lawmaker’s call for adult use cannabis legalization signals real momentum ahead of the 2026 legislative cycle. For one of the largest East Coast markets, this marks a meaningful shift toward new business and investment opportunities.

A cannabis business owner running for Congress signals a shift from outside advocacy to direct representation in federal policymaking. The move highlights the industry’s growing political maturity and push for practical reform.

As lawmakers debate tighter hemp restrictions, enforcement uncertainty is emerging as the biggest risk for operators. Federal and state conflict will shape how rules are applied, affecting competition, distribution, and compliance planning.

Trump’s push to reschedule cannabis signals growing federal recognition of medical use and opens pathways for expanded research and clearer CBD oversight. While not full legalization, the move reflects momentum rather than restriction.

A proposed federal cannabis legalization commission signals that lawmakers are seeking a real national framework. While it does not mean immediate legalization, it marks continued forward movement in federal cannabis policy.

The United States has officially moved cannabis to Schedule III, acknowledging accepted medical use and reducing long standing federal barriers. While cannabis remains federally illegal, the shift opens new pathways for research, healthcare integration, and industry stability.

Despite federal reclassification, cannabis businesses still face major barriers accessing traditional banking services. Large financial institutions remain cautious, forcing operators to rely on smaller lenders and alternative financing.

If cannabis moves to Schedule III, federal barriers around research, medical development, banking, and penalties could ease significantly. While cannabis would remain federally regulated, the change could unlock long awaited pathways for growth and stability.

Markets are reacting as President Trump is expected to address federal cannabis policy and possible reclassification to Schedule III. The move could ease banking, research, and tax barriers while keeping cannabis federally illegal.